Health Canada: Plan to Phase out Most Uses of Clothianidin and ThiamethoxamPublished on September 18, 2018
Author: Bhavesh Patel
Neonicotinoids are a class of pesticides used to control insects on a variety of agricultural crops, including seed treatments, and on turf and ornamental plants. Although primarily used in agriculture, neonicotinoids can also be used for other applications such as controlling cockroaches and ants. Clothianidin and thiamethoxam have been measured at levels that are harmful to aquatic insects, a key source of food for fish, birds and other animals.
Following special reviews for two neonicotinoid pesticides, clothianidin and thiamethoxam, Health Canada’s Pest Management Regulatory Agency has found that these substances are being measured at levels that are harmful to aquatic insects. Based on these findings, Health Canada is proposing to phase out all outdoor agricultural and turf uses for clothianidin, and all outdoor agricultural and ornamental uses for thiamethoxam, in the next three to five years.
Health Canada has published proposed special review decisions for both pesticides. These proposals will be subject to a 90-day consultation period, during which stakeholders and interested parties can submit comments on the proposed decision and provide additional data for consideration. Final special review decisions are expected to be announced at the end of 2019 and will take into consideration any comments or new information received during the consultation period.
Thank you for reading Regulated Affairs, the CAPRA Blog. CAPRA is a non-profit organization dedicated to providing professional development opportunities in Regulatory Affairs. Feel free to share our blog posts and join us on social media.
Pragmatic Clinical Trials: Testing Treatments in the Real-World
What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...
The FDA Announces Proposed Rule: Nonprescription Drug Product with an Additional Condition for Nonprescription Use – June 28, 2022
The FDA is announcing the availability of the proposed rule Nonprescription Drug Product with an Additional Condition for Nonprescription Use (Docket No. FDA-2021-N-0862)....